Backed by In­di­an biosim gi­ant Bio­con, bis­pecifics play­er Bicara de­buts with $40M and sol­id tu­mors on the radar

Best known state­side for its biosim­i­lars pact with My­lan, In­di­an gener­ics play­er Bio­con has long run a much small­er R&D unit for in-house on­col­o­gy drugs. Now, with at least one of those can­di­dates show­ing promise, Bio­con is prop­ping up a US-based biotech to get things off the ground.

Bio­con will shell out $40 mil­lion and spin off bis­pe­cif­ic an­ti­body play­er Bicara — head­quar­tered in Cam­bridge, MA — which is cur­rent­ly test­ing its lead com­pound along­side Mer­ck’s Keytru­da against sol­id tu­mors, the com­pa­ny said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER